Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. [electronic resource]
Producer: 20170721Description: 2969-79 p. digitalISSN:- 1527-7755
- Aged
- Antibodies, Monoclonal -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- B7-H1 Antigen -- biosynthesis
- Carboplatin -- administration & dosage
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Cisplatin -- administration & dosage
- Cohort Studies
- Deoxycytidine -- administration & dosage
- Disease-Free Survival
- Dose-Response Relationship, Drug
- ErbB Receptors -- genetics
- Female
- Humans
- Lung Neoplasms -- drug therapy
- Male
- Middle Aged
- Nivolumab
- Pemetrexed -- administration & dosage
- Proto-Oncogene Proteins p21(ras) -- genetics
- Survival Rate
- Gemcitabine
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article
There are no comments on this title.
Log in to your account to post a comment.